Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.

Details on agency responses to committee recommendations can be found under the Performance Measures section for each committee in the fields “Agency Feedback” and “Agency Feedback Comment.”

HHS - 1001 - President's Cancer Panel - Statutory (Congress Created)


Committee NamePresident's Cancer PanelAgency NameDepartment of Health and Human Services
Fiscal Year2022Committee Number1001
Original Establishment Date11/20/1985Committee StatusChartered
Actual Termination Date Committee URL
New Committee This FYNoPresidential Appointments*Yes
Terminated This FYNoMax Number of Members*3
Current Charter Date5/31/2020Designated Fed Officer Position Title*SPECIAL ASSISTANT TO THE DIRECTOR
Date Of Renewal Charter5/31/2022Designated Federal Officer Prefix
Projected Termination Date Designated Federal Officer First Name*MAUREEN
Exempt From Renewal*NoDesignated Federal Officer Middle NameR.
Specific Termination AuthorityDesignated Federal Officer Last Name*JOHNSON
Establishment Authority*Statutory (Congress Created)Designated Federal Officer SuffixPHD
Specific Establishment Authority*42 U.S.C. 285a-4Designated Federal Officer Phone*(240) 781-3327
Effective Date Of Authority*11/20/1985Designated Federal Officer Fax*(240) 541-4505
Exempt From EO 13875 Discretionary CmteNot ApplicableDesignated Federal Officer Email*
Committee Type*Continuing
Committee Function*National Policy Issue Advisory Board


Agency Recommendation*Continue
Legislation to Terminate RequiredNot Applicable
Legislation StatusNot Applicable
How does cmte accomplish its purpose?*The committee is composed of three members who provide advice and recommendations to the President of the United States in the areas of policy, health care, research, and information dissemination. The Panel monitors the development and execution of the activities of the National Cancer Program. Any delays or blockages in rapid execution of the Program are immediately brought to the attention of the President. The Panel conducts meetings throughout the country that serve as a forum for the scientific community and for the public. Based on expert testimony presented and discussions occurring at these meetings, the Panel makes recommendations, some of which have affected the initiation of new NCI programs and the implementation of existing priorities. A series of meetings occurred in FY21 that focused on improving resilience and equity in cancer screening. In FY22, based on the FY21 series of meetings, the Panel members developed recommendations and wrote the final report entitled "Closing Gaps in Cancer Screening: Connecting People, Communities, and Systems to Improve Equity and Access". The recommendations covered breast, cervical, colorectal and lung cancer and included improving and aligning communication; facilitating equitable access; strengthening workforce collaborations, and creating effective health IT.
How is membership balanced?*The President's Cancer Panel consists of three persons appointed by the President, who by virtue of their training, experience and background, are exceptionally qualified to appraise the National Cancer Program. It is mandated that at least two of the members of the Panel will be distinguished scientists or physicians.
How frequent & relevant are cmte mtgs?*Meetings are generally held not less than four times each fiscal year at the call of the Chair. Due to the members developing recommendations and writing the final report, no meetings were held in FY22.
Why advice can't be obtained elsewhere?*The President's Cancer Panel was established by law, and the chairman submits to the President, the Secretary, and the Congress an annual evaluation of the National Cancer Program and suggestions for improvements. The Panel also submits such other reports as the White House requests. The quality, scope, and balance of advice from this Panel cannot be obtained from NIH staff or from other established sources because the membership of the Panel is constituted to meet the specific requirements of its mandated mission to appraise the National Cancer Program.
Why close or partially close meetings?N/A
Recommendation RemarksMax Number of Members Total: The Charter allows the Committee to have 3 authorized members, which equals to the total of 3 of members.

Members: The terms for Mr. Robert Ingram, Dr. Edith Mitchell and Dr. John Williams changed due to administrative extensions. As such, their term of service end dates are different then what was reported on the FY21 ACR.

Meetings: Due to the members developing recommendations and writing their final report, no meetings were held in FY22.

Reports: This committee produced the public report entitled "Closing Gaps in Cancer Screening: Connecting People, Communities, and Systems to Improve Equity and Access".

The DFO and Committee Decision Maker positions are held by the same individual because of the assignment of responsibilities within the Institute.


Outcome Improvement To Health Or Safety*YesAction Reorganize Priorities*Yes
Outcome Trust In GovernmentYesAction Reallocate ResourcesNo
Outcome Major Policy ChangesYesAction Issued New RegulationsNo
Outcome Advance In Scientific ResearchYesAction Proposed LegislationNo
Outcome Effective Grant MakingNoAction Approved Grants Or Other PaymentsNo
Outcome Improved Service DeliveryYesAction OtherNo
Outcome Increased Customer SatisfactionYesAction CommentN/A
Outcome Implement Laws/Reg RequirementsYesGrants Review*No
Outcome OtherNoNumber Of Grants Reviewed0
Outcome CommentThe PCP, because it is charged under the Cancer Act to assess the program, has indicated that it has responsibilities in all areas of the cancer program which includes the above.Number Of Grants Recommended0
Cost Savings*Unable to DetermineDollar Value Of Grants Recommended$0.00
Cost Savings CommentNIH supported basic and clinical research accomplishments often take many years to unfold into new diagnostic tests and new ways to treat and prevent diseases.Grants Review CommentN/A
Number Of Recommendations*203Access Contact Designated Fed. Officer*Yes
Number Of Recommendations CommentIn addition to the eight recommendations made in the "Closing Gaps in Cancer Screening: Connecting People, Communities, and Systems to improve Equity and Access" report, in FY 2022 the committee made a motion to form a Working Group on Access to Genomic Testing for Cancer Management. The motion passed unanimously.Access Agency WebsiteYes
% of Recs Fully Implemented*0.00%Access Committee WebsiteYes
% of Recs Fully Implemented CommentDue to the large breadth and complexity of the recommendations made by this committee, NCI staff is unable to determine which recommendations have been fully or partially implemented solely in response to this committee's activities.Access GSA FACA WebsiteYes
% of Recs Partially Implemented*0.00%Access PublicationsYes
% of Recs Partially Implemented CommentDue to the large breadth and complexity of the recommendations made by this committee, NCI staff is unable to determine which recommendations have been fully or partially implemented solely in response to this committee's activities.Access OtherYes
Agency Feedback*YesAccess CommentInformation on the PCP can be found at the President’s Cancer Panel website at Findings are also communicated through mailings and in person briefings.
Agency Feedback Comment*Information is provided to the public at each meeting. The public can view information related to the Committee through the committee’s official website.Narrative Description*The goal of NIH research is to acquire new knowledge to help prevent, detect, diagnose, and treat disease and disability, from the rarest genetic disorder to the common cold, resulting in better health for everyone. Annual identification and assessment of the issues facing the National Cancer Program contribute to the advancement of this mission and the development of the NIH strategic plan in regards to cancer. Over its approximately 40 year history, the Panel has engaged in active dialogue with all participants in the National Cancer Program [the Program] in an effort to assess the progress and coordination of the Program. The Panel has generally held four or more meetings in each series to gather information and to stimulate discussion among prominent scientists, clinicians, academia, business, industry and the government. Recent topics have included how to increase the uptake of the human papillomavirus (HPV) vaccine; the potential for connected health strategies and technologies to engage and activate individuals and patients, with the ultimate goal of improving cancer-related outcomes; ensuring patients' access to high-value cancer care; and accessing and improving cancer screening drugs. The current topic being explored is how lessons from COVID-19 and beyond can help to improve resilience and equity in cancer screening. As a link between the President and the public on cancer issues, the Panel provides information that informs cancer policy at the Executive level through its mandate to assess the efficacy of the National Cancer Program. The meetings of the Panel present a unique opportunity to identify and bring together the vast research, health care and manpower resources of this Nation by eliciting public testimony in assessment of the National Cancer Program. The PCP meetings provide the President with the means to identify both the strengths and the weaknesses of the National Cancer Program and the opportunity to seek out needed adjustments. The Panel fills a critical need as the sometimes costly screening, treatment, and technological advances made possible through cancer research must be successfully and equitably applied throughout the country to alleviate suffering and death caused by cancer.
Hide Section - COSTS


Payments to Non-Federal Members*$6,084.00Est Payments to Non-Fed Members Next FY*$28,392.00
Payments to Federal Members*$0.00Est. Payments to Fed Members Next FY*$0.00
Payments to Federal Staff*$291,939.00Estimated Payments to Federal Staff*$299,821.00
Payments to Consultants*$0.00Est. Payments to Consultants Next FY*$0.00
Travel Reimb. For Non-Federal Members*$0.00Est Travel Reimb Non-Fed Members nextFY*$9,272.00
Travel Reimb. For Federal Members*$0.00Est Travel Reimb For Fed Members*$0.00
Travel Reimb. For Federal Staff*$0.00Est. Travel Reimb to Fed Staff Next FY*$3,532.00
Travel Reimb. For Consultants*$0.00Est Travel Reimb to Consultants Next FY*$0.00
Other Costs$264,114.00Est. Other Costs Next FY*$266,755.00
Total Costs$562,137.00Est. Total Next FY*$607,772.00
Date Cost Last Modified11/3/2022 6:29 AMEst. Fed Staff Support Next FY*2.00
Federal Staff Support (FTE)*2.00Est Cost RemarksProjected costs for FY23 were increased in the event that in-person/hybrid meetings resume.
Cost RemarksThere were less meetings held in FY22 and in addition those held were virtually due to the ongoing COVID-19 pandemic as such the FY22 Operating Costs are lower than what was projected on the FY21 FOP. The federal staff cost and staff support years differences between FY21 and FY22 are due to staffing changes and the realignment of work in support of the PCP.  
Hide Section - Interest Areas

Interest Areas

Health and Health Research


To View all the members, meetings and advisory reports for this committee please click here


No Documents Found



Data from Previous Years

ActionCommittee System IDCommittee NameFiscal Year
 COM-040526President's Cancer Panel2021
 COM-038801President's Cancer Panel2020
 COM-036683President's Cancer Panel2019
 COM-034898President's Cancer Panel2018
 COM-002028President's Cancer Panel2017
 COM-002225President's Cancer Panel2016
 COM-003838President's Cancer Panel2015
 COM-004410President's Cancer Panel2014
 COM-006269President's Cancer Panel2013
 COM-006548President's Cancer Panel2012
 COM-008226President's Cancer Panel2011
 COM-008779President's Cancer Panel2010
 COM-010367President's Cancer Panel2009
 COM-010746President's Cancer Panel2008
 COM-012263President's Cancer Panel2007
 COM-012504President's Cancer Panel2006
 COM-013756President's Cancer Panel2005
 COM-014416President's Cancer Panel2004
 COM-015700President's Cancer Panel2003
 COM-016768President's Cancer Panel2002
 COM-017897President's Cancer Panel2001
 COM-018492President's Cancer Panel2000
 COM-019822President's Cancer Panel1999
 COM-020610President's Cancer Panel1998
 COM-021459President's Cancer Panel1997